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Salmonella species cause substantial morbidity, mortality, and disease burden globally 
with multiple clinical syndromes. A protective host defense to Salmonella infection 
requires both T-cell (cell-mediated) and B-cell (humoral) immune response. Current 
vesicle vaccine platforms include inactivated, non-replicating, or synthetic liposomes 
which do not produce a robust immune response because they lack foreign distinctness 
and complexity. Membrane vesicles (MVs), released in a conserved process by Gram-
negative bacteria, are discrete, spherical nano-particles that are composed of outer 
membrane and periplasmic constituents including lipopolysaccharides and proteins. 
MVs are promising vaccine candidates for the following reasons: their intrinsic adjuvant 
properties, genetically malleability via the parental bacterial strain that can alter vaccine 
efficacy, a minimal production cost, and they are stable in powder form. As biologically 
derived but nonreplicating particles they are important in the vaccine strategy for 
immunocompromised populations. My findings reveal MVs posses important 
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inflammatory properties that demonstrate a viable vaccine platform potential for 
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APC Antigen presenting cell 
DC Dendritic cell 
IFN Interferon 
IL Interleukin 
LB Luria-bertani broth 
LPS Lipopolysaccharides 
MLN Mesenteric lymph nodes 
MV Membrane vesicle 
Mφ Macrophage 
PMN Polymorphonuclear cell 
STM Salmonella typhimurium 
TFF Tangential flow filtration 
TNF Tumor necrosis factor 
TSB Tryptic soy broth 
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Microbes are ubiquitous in the world, and some cause disease. Yet despite the constant 
exposure, illness does not persistently occur. This is due to the immune system, a 
collection of specialized cells and tissues that use specific biological structures and 
mechanisms in order to protect against disease by identifying then killing pathogens. In 
vertebrate animals there are two arms of the immune system that protect the body from 
infection, the innate branch and the adaptive branch. 
 
Innate host defenses 
Innate host defenses are genetically encoded and do not improve over time or after 
multiple exposures. Innate immunity includes physical barriers, like the skin and 
epithelial cells that line mucosal surfaces, which block the entrance of microbes (13). 
Mucosal membranes line the respiratory, digestive, and urogenital tracks, and secrete 
antimicrobial chemicals and enzymes, like the small cationic peptides defensins, an 
antimicrobial protein against various microorganisms (4, 5). Besides physical and 
microbicidal barriers, the innate immune system also uses non-specific effector cells that 
act rapidly against invaders recognized as foreign. One such example of a non-specific 
effector cells are macrophages, which reside in almost all the tissues of the body and are 
_______________ 
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often the first immune cells to encounter invading pathogens. Mφ engulf and kill 
pathogens in a process called phagocytosis, help induce inflammation by signaling and 
recruiting other effector cells, and present antigen to activate the adaptive immune 
system (7, 13). 
 
Adaptive host defenses 
The adaptive branch of the immune system responds later after the innate defenses.  
Although innate responses control infection, clearing an infection lies with the adaptive 
immune response. Adaptive immunity is often referred to as “specific immunity” 
because it responds to a specific foreign cell or protein. The components that immune 
cells respond to are termed epitopes and are unique to the pathogen. The adaptive 
immune response is also capable of remembering each invader it encounters by keeping 
a collection of memory cells to specific epitiopes that respond faster and in greater 
magnitude (2). The adaptive response is closely linked to the innate response through 
cell-cell interactions of adaptive effector cells and APCs, which are required to activate 
the adaptive effector cells. This is the hallmark branch of the immune system and can be 
further divided into cell-mediated immunity or humoral immunity. Cell mediated 
immunity involves the T lymphocytes whose functions fall into three broads classes: 
cytotoxic, helper, and regulatory. Cytotoxic T cells kill host cells infected with 
intracellular pathogens, helper T cells are necessary to activate B cells, and regulatory T 
cells help control immune responses. B lymphocytes make up the humoral response and 
are responsible for the production of antibodies.  Antibodies help in the destruction of 
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foreign invaders and also provide us with long-term protection after clearing the 
infection.  B cells have unique surface receptors called the B cell receptors that are 
specific to different epitopes on pathogens. When a pathogenic antigen binds to the B 
cell receptor, the cell proliferates, differentiates into a plasma cell, and produces 
antibodies with identical antigen specificity (7, 13).  
 
Salmonella infection 
Salmonella enterica is a rod shaped, Gram-negative, facultative intercellular bacterium 
belonging to the Enterbacteriaceae family (17). Salmonella causes as many as 1.3 
billion cases of disease per year worldwide and as many as 200,000 deaths. In humans, 
multiple clinical syndromes include typhoid fever (enteric fever), enterocolitis, diarrhea, 
and bacteremia (3). Over 2,500 serovars, or classification groups based on surface 
antigens, have been identified. However, typhi and paratyphi, which cause typhoid 
fever, are exclusively pathogenic for humans (17). Our current understanding of typhoid 
pathogenesis comes from infecting susceptible mice with the serovar typhimurium that 
produces a disease with typhoid-like symptoms (3).  
 
Protective immunity to Salmonella 
In mice, the first cells that encounter Salmonella are intestinal epithelial cells, DCs, and 
Mφs (1, 15). Interaction with these cells leads to production and release of pro-
inflammatory cytokines and chemokines leading to a large influx of immune effector 
cells such as PMNs, DCs, and Mφs to the infected area. Some of the critical cytokines 
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for producing a robust immune response to STM include IFN-γ, TNF-α, and IL-12. 
TNF-α, in particular, activates macrophages ands enhances their toxic nitric oxide 
production to increase overall bacterial killing (3).  Pathogens may overwhelm the innate 
immune system and need adaptive immunity for host defense (Murphy). In previous 
studies, it has been determined that a protective host defense to Salmonella infection 
requires both T-cell (cell-mediated) and B-cell (humoral) immune response (1, 17).  
 
Current vaccine platforms 
A quality vaccine must develop a robust, protective immune response, stimulate both B 
and T cells, provide long lasting immunity, and have minimal adverse side effects (7). 
Current vaccine models that utilize live pathogens have been attenuated by random or 
directed mutagenesis. Some strains used include aroA-null, phoP-null, and waaL-null. 
The aroA-null mutant is deficient in an aromatic amino acid, the phoP-null mutant locks 
the bacterium in its intracellular conformation, and waaL-null mutants lack the O antigen 
in the LPS. Mutagenesis only works for pathogens that are known to have immunogenic 
properties. To date, around 100 genes are associated with virulence in Salmonella 
typhimurium, but there remains no vaccine. This is due to the fact that not all mutations 
create stable attenuated phenotypes. Some mutations do not attenuated the pathogen 
enough for safe administration, while others are so attenuated that they are unable to 
induce protection against a live, virulent Salmonella challenge. Historically, vesicle 
vaccines include non-replicating or synthetic liposomes. However, liposome vaccines do 
not produce a robust immune response because they lack foreign distinctness and 




Membrane vesicles (MVs) have been investigated for decades, but the physiological 
significance and utility has not been appreciated until recently (4). MVs are discrete, 
spherical nano-particles that are composed of outer membrane and periplasmic 
constituents including lipopolysaccharides (LPS) and proteins. The release of vesicles is 
a conserved process in Gram-negative bacteria, including many pathogens such as 
Salmonella, and they function as an alternate secretion pathway (1, 11). MV production 
in vivo may be one method by which bacteria interact with eukaryotic cells. They are 
interesting candidates for vaccines due to their intrinsic adjuvant properties and 
genetically malleability via the parental bacterial strain which can be used to alter 
vaccine properties. MVs also involve a minimal production cost/complexity and are 
stable in powder form. MVs are biologically derived but are non-replicating particles, 
which makes them important in the vaccine strategy for immunocompromised 
populations that cannot receive live attenuated vaccines without complications.  In 
previous studies, MV vaccination in mice induced pathogen-specific B-cell and T-cell 
host defenses and protective immunity against subsequent live pathogen challenge (1).  




Bacterial strains and cultures  
The bacterial strains used in this study are both S. typhimurium STM14028 strains 
received from Dr. Andrews-Polymenis. RA100 is a wild-type virulent strain and RA133 
is a del-STM3713::KanR (waaL-null with kanamycin resistance). STM strains were 
grown in LB, TSB, or on LB agar plates at 37°C. 
 
Tissue cultures 
J774-A1 Mφs were maintained in a humidified incubator in an atmosphere of 5% CO2 at 
37°C and cultured in RPMI complete medium supplemented with 5% fetal calf serum 
(FCS; Gibco-Invitrogen), 2-mercapthoethanol (50 uM), Pen/Step antibiotics 
(100ug/mL), and Gentamicin antibiotics (50ug/mL).  
 
Glassware preparation 
All glassware used for the isolation and purification of membrane vesicles was acid- 
washed in 5% phosphate free Contrad detergent and rinsed thoroughly in distilled water. 
All interior surfaces were rinsed with 1N HCl for 10 minutes and rinsed thoroughly in 
distilled water. Media was made in the Fernback flasks with Millipore water, autoclaved, 
and stored 1-4 days with an airtight seal until use. Sorvall centrifuge bottles and glass 
vacuum filter bottles were autoclaved and stored with sealed caps. 
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Salmonella antigens 
Heat inactivated (HKSTM) antigens were prepared from10 mL LB cultures grown 
overnight at 37°C with shaking (200 rpm). HKSTM were pelleted by centrifugation 
(14,000 rpm for 15 min at 25°C) and resuspended to 2x109 CFU/mL in Millipore water, 
aliquoted, and stored at -20°C. The following antigens were previous prepared by 
Kristina Ryden or other lab alumni: phorbol myristate acetate (PMA) at working 
concentration 20ng/mL stored at -20oC, concanavalin A from Canavalia ensiformis 
(ConA) at working concentration 0.1ug/mL stored at -20oC, and lipopolysaccharide 
(LPS) at 1mg/mL stored at 4oC. 
 
Isolation and purification of MVs (Figure 1) 
Vesicles were harvested from culture supernatants of bacteria grown to mid-log phase. A 
35 mL TSB in a 50 ml conical was inoculated with a single colony and incubated 
overnight at 37°C with shaking (200 rpm) and used to inoculated 1 L TSB (acid-washed 
Fernbach flask) and incubated 4 hours at 37°C with shaking (200 rpm) to an OD600 of 
~3. Bacteria were pelleted by centrifugation (9,000 x g for 30 min at 4°C) and the 
supernatant was decanted and passed through a 0.45 um filter. The supernatant was 
concentrated by either Amicon Ultra Millipore filters (100K cutoff) and centrifugation 
(2500 rpm for 10 min/spin at 4°C) or TFF (100K cassette) using gas sterilized tubing 
and reservoir. Vesicles were collected by ultracentrifugation (150,000 x g for 2 h at 
4°C), lyophilized, and resuspended to 1.0 mg/mL in Millipore water and stored at 4°C. 
  8 
Grow starter culture O/N
Inoculate 1 L flask
Record start time
and OD600
Record end time 
and OD600






Pellet MV’s by 
ultracentrifugation










Figure 1.  MV Isolation Flow Chart. This depicts the isolation and purification of MVs 
developed during the course of this project. 
 
Particle analysis of MVs 
Concentrated MVs were lyophilized once or twice and reconstituted to 1mg/mL. The 
first dilution of 1:10 used 150uL MV sample and 1500uL Millipore ultra pure H2O. The 
second dilution of 1:3 used 1mL from the 1:10 sample and 3mL Millipore ultra pure 
H2O. The particle analysis requires a 3mL sample taken from the final dilution. The 
samples were analyzed in the Slahtz lab in the Chemical Engineering Department. 
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Flow cytometry and intracellular cytokine staining (ICS) 
Production of cytokines by J774-A1 Mφs was detected by ICS using a method previous 
optimized by the Alaniz lab. 2 x 105 macrophages (in RPMI-C) were coincubated with 
the indicated titrations of HKST, MVs, LPS, ConA, or PMA in single wells of 96-well 
U-bottom tissue culture plates. Plates incubated at 37°C in 5% CO2 for 4 or 24 hrs. 
GolgiPlug was added (1/1000 dilution) for the final 4 hr in 24 hr stimulations or at the 
beginning for 4 hour stimulations. After stimulation, cells were washed twice in cold 
PBS plus 0.5% (w/v) BSA (Sigma Aldrich) (PBSA), and surface stained with A488-
labeled Abs to murine CD11b. Stained cells were fixed on ice with 2% 
paraformaldehyde and permeabilized with Perm/Wash buffer, followed by staining with 
PE-labeled Abs to murine TNF-  and APC-labeled Abs to murine IL-12. Cells were 
resuspended in PBSA and stored at 4°C in the dark until analysis. Unstained, 
unstimulated cells were used as negative controls. Data were acquired on a FACS Aria 
and analyzed using FlowJo Software. 
 
Mouse immunization 
Female C57Bl6 mice were used at 17- 18 weeks of age. Mice were immunized 
intraperitoneal with 50-100ng of RA100 MVs and the control group received PBS. 
Three days post injection 1 mouse was taken from each group for a cytokine harvest. 
Organs from individual mice (spleen, liver, Peyer’s patches, MLN, and blood) were 
homogenized in sterile 1x-NP40 using a motorized homogenizer (Omni International). 
Homogenates were spun down (1400 rpm for 10 min at 25oC) and filter sterilized using a 
  10 
0.2 um syringe filter and 25 gauge needle. Samples were stored incorrectly at 4oC for 
several days before being moved to -20oC. All mice were housed in specific pathogen-
free conditions and cared for in accordance with Animal Care and Use Committee 
guidelines. 
 




Salmonella MVs are nano-scale particles  
When evaluated in the particle analyzer, MVs lyophilized once had a mean diameter of 
179.9nm and a range of 50-500nm (Figure 2). The MVs lyophilized twice showed two 
distinct ranges of diameters. The first ranged 158.11-666.76nm and the second grouping 
ranged from 3.749-11.858um. Multiple lyophilizations must cause the individual MVs to 
fuse together and form much larger vesicles. This indicated that single lyophilization 
proved to be the best method of retaining the MVs natural form while treating them as a 
vaccine product.  
  





Figure 2. MV Particle Size Analysis, Electron Micrograph. MVs were isolated from 
RA100 a wild type strain of S. typhimurium 14028. (A) Electron micrograph obtained 
from: Alaniz, R.C., B.L. Deatherage, J.C. Lara, and B.T. Cookson. 2007. Membrane 
vesicles are immunogenic facsimiles of Salmonellae typhimurium that potentially 
activate DCs, prime B and T cell responses, and stimulate protective immunity in vivo. J 
Immunol 179: 7692-7701; bar = 250nm. (B) Particle size analysis of a 150uL aliquot of 
MVs, lyophilized once, and diluted (1:30) in Millipore ultra pure H2O to a volume of 
3mLs each.  
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Salmonella MVs activate Mφs in vitro 
Mφs reside tissues of the body and are often the first immune cells to encounter 
pathogens that invade the tissues. Mφs engulf and kill pathogens in a process called 
phagocytosis, help induce inflammation by signaling and recruiting other effector cells 
and present antigen to activate the adaptive immune system (1, 7). After MVs were 
incubated with J774-A1 Mφs, large amounts of TNF-α were produced. TNF-α is an 
important mediator in the inflammation by helping regulate the immune response and 
activating the acute phase response (7). IL-12 was not produced in any significant 
amount by the MVs or any other stimulants.  
 
Salmonella MVs are potent stimulators of Mφs in vitro 
MVs induce Mφs to produce TNF-α,  indicating they can activate pro-inflammatory 
pathways in macrophages. Compared to unstimulated cells, the MVs consistently 
activated over 80% of the cells to produce large amounts of TNF-α (Figure 3). LPS and 
HKSTM effectively activated macrophages but lost activity quicker after titration at 1:25 
and 1:125 respectively. The MVs retained activation properties through a dilution range 
of 1:10,000 indicating they are capable of stimulating host immune cells over broad 
concentrations. For Mφs stimulation experiments comparing the MVs and other 
antigens, 1:5 dilutions gave the clearest relationship of activating properties.  
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Figure 3.  Macrophage Stimulation with MVs. This figure shows the TNF-α production 
in murine J774 Mφs after a 4-hour stimulation with (B) MVs (50 µg/ml) or (A) no 
stimulents as a negative control. Percentages indicate proportion of J774 cells producing 
TNF-α of total cells.  
 
MVs activate the immune system in vivo 
MVs are composed of outer membrane and periplasmic constituents including LPS and 
proteins suggesting they can be recognized by the innate immune response and adaptive 
immune response specific for Salmonella (1, 4). To test this, 10 mice were 
intraperitoneal injected with 100ng of wild type (RA100) MVs in the initial 
immunization. Five days post injection; the mice appeared listless, hunched, and 
moribund. By day 5 end 8 of the 10 succumbed to their immunization. By day 14 only 
one mouse remained. This indicates the 100 ng dose induces a robust yet lethal pro-
inflammatory response and suggested lower doses would be better tolerated.  
 
TNF - α 
Unstimulated Cells Stimulated with MVs 
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Due to high mouse deaths the control group mice were taken for a new immunization: 3 
mice received 75ng MVs, 3 mice received 50ngs MVs, and the rest remained naive. 
Three days post injection, one of the 75ng vaccinated mouse died. One mouse from each 
group was sacrificed for a cytokine harvest. Several organs in each mouse showed 
increased amount of TNF-α produced when compared to the naïve mouse. The results 
can be found in Table 1. By day 5 post injection, both the 50ng and 75ng immunized 
mice succumbed.  
Table 1. Cytokine Harvest Results 
 50 ng Mouse 75 ng Mouse 
Organs TNF-α (pg/mL) 
Peyer's 
Pathches 439.5 213.9 
   
MLN 211.4 115.75 
   
Spleen 64.5 ---- 
 
 
Pro-inflammatory properties and mutant strains 
Based on the overwhelming potency of the wild type MVs in vivo, I hypothesized that 
MVs with reduced pro-inflammatory properties would allow for better outcomes after 
mouse immunization. Attentions were directed towards the waaL-null mutant, a 
necessary enzyme for the creation of the O antigen in LPS. LPS is a complex glycolipid 
located in the outer membrane of Gram-negative bacteria that contributes to 
permeability-barrier properties and stability of the outer membrane (14). LPS molecules 
can be subdivided into three structurally distinct regions. The hydrophobic lipid A forms 
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the membrane lipid portion and is responsible for the endotoxic properties of LPS. The 
core oligosaccharide (core OS) serves as a link between lipid A and the outer 
polysaccharide repeating unit known as O antigen. O antigen plays a direct role in 
virulence, contributing to the resistance of gram-negative bacteria to complement-
mediated serum killing (8).  
 
 The ligation of O antigen polysaccharide to lipid A-core oligosaccharide is a late step in 
the formation of LPS (10). WaaL proteins are ligases and currently the only protein 
known to be involved in the addition of the O anitgen. WaaL proteins in Escherichia coli 
and Salmonella share highly conserved predicted membrane topology and overall 
secondary structure (6). WaaL mutants produce rough LPS, meaning they lack O antigen 
repeat units (12). I hypothesized that the RA133 MVs would be less likely to overwhelm 
the immune system and cause death in vivo, but still be immunogenic due to the 
presence of other surface antigens. Comparisons of the two strains can be found in Table 
2. 




Stock # Strain Phenotype: Genotype Source 
RA100 
S. typhimurium 
STM14028 (ATCC) wild type: virulent 
Dr. Andrews-
Polymenis 





(waaL-null, kanamycin resistant) 
Dr. Andrews-
Polymenis 
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Wild type and waaL-null Salmonella MVs both activate macrophages in vitro 
Initial comparison data of the wild type and mutant HKSTM and MVs showed that both 
strains are potent activators of TNF-α production in J774-A1 Mφs. Similar to the wild 
type MVs, RA133 MVs activated over 60% of the cells up to a dilution of 1:10,000 and 
retain activating properties over more concentrations than the RA133 HKSTM (Figure 
4). There was not a distinct difference in Mφ activation between the wild type strain and 
RA133. 
RA 133 MVs   RA 100 MVs 
 





Figure 4. RA 133 and RA 100 MV Comparison. This figure shows the TNF-α 
production in murine J774 Mφs after a 4-hour stimulation with RA 133 MVs (50 µg/ml) 
and RA 100 MVs (50 µg/ml). Percentages indicate proportion of J774 cells producing 






TNF - α 
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CHAPTER IV 
SUMMARY AND CONCLUSIONS 
 
Summary 
The study of MVs spans decades and several groups have demonstrated their biological 
function as an alternate secretion system (11).  However, more study is needed as the 
mechanisms for MV regulation, the MV role in bacterial pathogenesis, and the outcome 
of MV interactions with host defenses are still unclear. This is especially important in 
regards to pathogens such as Salmonella, which interact with the host immune system at 
multiple stages of infection (9). This project demonstrated some of the outcomes from 
interaction between the MVs and the host immune response. 
 
Some the first cells that encounter Salmonella during a course of infection are the 
intestinal epithelial cells, DCs, and Mφs (3). The MVs are composed of outer membrane 
and periplasmic constituents that can be recognized as pathogen associated molecular 
patterns by the host immune system (1, 4). Interactions with these cells produce pro-
inflammatory cytokines and chemokines that cause a large influx of immune effector 
cells which, in turn, are responsible for producing a robust immune response in the 
Salmonella infection. A good vaccine for Salmonella would induce protective immunity 
without the active infection from a virulent bacterium.  
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Conclusions 
I had hypothesized that MVs would be potent stimulators of Mφs due to their 
composition of out membrane constituents and that MVs would induce a pro-
inflammatory response in vitro and in vivo which could be applicable to a vaccine 
platform.  
 
The ability of MVs to induce a pro-inflammatory response was tested by incubating the 
MVs with J774-A1 Mφs in vitro. Both wild-type MVs and waaL-null mutant MVs 
consistently active ted a significant percentage of the Mφs to produce large amounts of 
TNF-α (Figures 3, 4). This demonstrates that both strains of MVs are stimulants for a 
protective immune response. The MVs also retained activation properties through a 
dilution of 1:10,000 indicating they are capable of stimulating host immune cells over 
broad concentrations and in very minute amounts. This shows that MVs can persist 
without the use of an adjuvant and are sufficient to robustly activate immune effector 
cells. 
 
The pro-inflammatory capabilities of MVs were also tested in vivo by immunizing 
C57Bl6 mice in doses of 100 ng, 75 ng, and 50 ng MVs per mouse. In the course of 
several days the mice were visibly affected by the immunization and eventually 
succumbed as a result from the MV injection. The cytokine harvest showed elevated 
levels of TNF-α in immunized mice. This shows that the MV immunization produced 
robust yet lethal pro-inflammatory response. A dosage titration would better evaluate 
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tolerance levels for future studies. Also, other routes of injection should be considered 
due to the systemic response of intraperitoneal injections.  
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